Pharmerica Corporation (NYSE:PMC) has received an average rating of “Hold” from the seven brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $29.25.

Several research firms have issued reports on PMC. ValuEngine upgraded Pharmerica Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, October 31st. Barrington Research lowered Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th. KeyCorp lowered Pharmerica Corporation to an “overweight” rating in a research note on Tuesday, August 8th. Zacks Investment Research upgraded Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a research note on Wednesday, September 27th. Finally, UBS AG reiterated a “neutral” rating and set a $29.25 price objective (up from $26.00) on shares of Pharmerica Corporation in a research note on Thursday, August 3rd.

Pharmerica Corporation (NYSE:PMC) opened at $29.10 on Friday. The company has a market capitalization of $905.56, a price-to-earnings ratio of 15.24, a P/E/G ratio of 1.27 and a beta of 0.82. Pharmerica Corporation has a 12-month low of $22.00 and a 12-month high of $29.50. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.57 and a quick ratio of 1.79.

Pharmerica Corporation (NYSE:PMC) last issued its earnings results on Thursday, November 9th. The company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $595.10 million during the quarter, compared to the consensus estimate of $596.80 million. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. analysts predict that Pharmerica Corporation will post 1.92 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Pharmerica Corporation (PMC) Receives Average Rating of “Hold” from Analysts” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/10/pharmerica-corporation-pmc-receives-average-rating-of-hold-from-analysts.html.

Several large investors have recently made changes to their positions in PMC. BlackRock Inc. increased its stake in shares of Pharmerica Corporation by 51,604.4% in the first quarter. BlackRock Inc. now owns 3,975,551 shares of the company’s stock valued at $93,027,000 after buying an additional 3,967,862 shares in the last quarter. Royce & Associates LP increased its stake in shares of Pharmerica Corporation by 966.5% in the second quarter. Royce & Associates LP now owns 426,600 shares of the company’s stock valued at $11,198,000 after buying an additional 386,600 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Pharmerica Corporation by 40.1% in the second quarter. Victory Capital Management Inc. now owns 1,294,142 shares of the company’s stock valued at $33,971,000 after buying an additional 370,266 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Pharmerica Corporation by 3,799.6% in the third quarter. SG Americas Securities LLC now owns 281,007 shares of the company’s stock valued at $8,234,000 after buying an additional 273,801 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Pharmerica Corporation in the third quarter valued at $7,031,000. Institutional investors own 86.01% of the company’s stock.

Pharmerica Corporation Company Profile

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.